These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 32765056)

  • 1. Mirogabalin in Japanese Patients with Renal Impairment and Pain Associated with Diabetic Peripheral Neuropathy or Post-Herpetic Neuralgia: A Phase III, Open-Label, 14-Week Study.
    Baba M; Takatsuna H; Matsui N; Ohwada S
    J Pain Res; 2020; 13():1811-1821. PubMed ID: 32765056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and Efficacy of Mirogabalin for Peripheral Neuropathic Pain: Pooled Analysis of Two Pivotal Phase III Studies.
    Kato J; Baba M; Kuroha M; Kakehi Y; Murayama E; Wasaki Y; Ohwada S
    Clin Ther; 2021 May; 43(5):822-835.e16. PubMed ID: 34059327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled 14-Week Study of Mirogabalin in Chinese Patients with Diabetic Peripheral Neuropathic Pain.
    Guo X; Yu Y; Zhang Y; Sun L; Li Y; Song B; Hang L; Baba M; Wasaki Y; Kikumori K; Murayama E
    Pain Ther; 2024 Aug; 13(4):937-952. PubMed ID: 38896199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Results of Mirogabalin Treatment for Diabetic Peripheral Neuropathic Pain in Asian Subjects: A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Study.
    Baba M; Kuroha M; Ohwada S; Murayama E; Matsui N
    Pain Ther; 2020 Jun; 9(1):261-278. PubMed ID: 32052264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mirogabalin for the treatment of diabetic peripheral neuropathic pain: A randomized, double-blind, placebo-controlled phase III study in Asian patients.
    Baba M; Matsui N; Kuroha M; Wasaki Y; Ohwada S
    J Diabetes Investig; 2019 Sep; 10(5):1299-1306. PubMed ID: 30672128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Add-on Mirogabalin to NSAIDs in Lumbar Spinal Stenosis with Peripheral Neuropathic Pain: A Randomized, Open-Label Study.
    Nikaido T; Takatsuna H; Tabata S; Shiosakai K; Nakatani T; Konno SI
    Pain Ther; 2022 Dec; 11(4):1195-1214. PubMed ID: 35857196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mirogabalin for Central Neuropathic Pain After Spinal Cord Injury: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study in Asia.
    Ushida T; Katayama Y; Hiasa Y; Nishihara M; Tajima F; Katoh S; Tanaka H; Maeda T; Furusawa K; Richardson M; Kakehi Y; Kikumori K; Kuroha M
    Neurology; 2023 Mar; 100(11):e1193-e1206. PubMed ID: 36517235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term safety and efficacy of mirogabalin in Asian patients with diabetic peripheral neuropathic pain.
    Baba M; Matsui N; Kuroha M; Wasaki Y; Ohwada S
    J Diabetes Investig; 2020 May; 11(3):693-698. PubMed ID: 31722446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Safety and Efficacy of Mirogabalin for Central Neuropathic Pain: A Multinational, Phase 3, 52-Week, Open-Label Study in Asia.
    Ushida T; Katayama Y; Hiasa Y; Nishihara M; Tajima F; Katoh S; Tanaka H; Maeda T; Furusawa K; Kakehi Y; Kikumori K; Kuroha M
    Pain Ther; 2023 Aug; 12(4):963-978. PubMed ID: 37115464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term safety and efficacy of mirogabalin in Asian patients with postherpetic neuralgia: Results from an open-label extension of a multicenter randomized, double-blind, placebo-controlled trial.
    Kato J; Matsui N; Kakehi Y; Murayama E; Ohwada S
    Medicine (Baltimore); 2020 Sep; 99(36):e21976. PubMed ID: 32899037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and Safety of a Single Oral Dose of Mirogabalin in Japanese Subjects With Varying Degrees of Renal Impairment.
    Kato M; Tajima N; Shimizu T; Sugihara M; Furihata K; Harada K; Ishizuka H
    J Clin Pharmacol; 2018 Jan; 58(1):57-63. PubMed ID: 28834546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of mirogabalin (DS-5565) for the treatment of diabetic peripheral neuropathic pain: a randomized, double-blind, placebo- and active comparator-controlled, adaptive proof-of-concept phase 2 study.
    Vinik A; Rosenstock J; Sharma U; Feins K; Hsu C; Merante D;
    Diabetes Care; 2014 Dec; 37(12):3253-61. PubMed ID: 25231896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of mirogabalin treatment in patients with diabetic peripheral neuropathic pain: A systematic review and meta-analysis of randomised controlled trials.
    Alyoubi RA; Alshareef AA; Aldughaither SM; Aljaroudi AM; Alabdulwahed A; Alduraibi FM; Masoud AT; Abu-Zaid A
    Int J Clin Pract; 2021 May; 75(5):e13744. PubMed ID: 32991782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Mirogabalin (DS-5565) on Patient-Reported Pain and Sleep Interference in Patients with Diabetic Neuropathic Pain: Secondary Outcomes of a Phase II Proof-of-Concept Study.
    Merante D; Rosenstock J; Sharma U; Feins K; Hsu C; Vinik A;
    Pain Med; 2017 Nov; 18(11):2198-2207. PubMed ID: 28371941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of Mirogabalin in Healthy Chinese Participants: A Randomized, Double-Blind, Placebo-Controlled Study.
    Li Y; Toyama K; Nakatsu T; Ishizuka H; Wu H; Cao G; Yu J; Wang Y; Liu X; Guo B; Wu J; Yu P; Hong Z; Zhang J; Wu X
    Adv Ther; 2023 Apr; 40(4):1628-1643. PubMed ID: 36790683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of add-on mirogabalin to conventional therapy for the treatment of peripheral neuropathic pain after thoracic surgery: the multicenter, randomized, open-label ADMIT-NeP study.
    Miyazaki T; Matsumoto K; Sato T; Sano I; Furukawa K; Shimoyama K; Kamohara R; Suzuki M; Kondou M; Ikeda N; Tabata S; Shiosakai K; Nagayasu T;
    BMC Cancer; 2024 Jan; 24(1):80. PubMed ID: 38225552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modeling an evaluation of the efficacy of the novel neuroanalgesic drug mirogabalin for diabetic peripheral neuropathic pain and postherpetic neuralgia therapy.
    Hong LM; Liu JM; Lin L; Huang CC; Chen R; Lin WW
    Eur J Pharm Sci; 2024 Jun; 197():106777. PubMed ID: 38649099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switching From Pregabalin to Mirogabalin in Patients with Peripheral Neuropathic Pain: A Multi-Center, Prospective, Single-Arm, Open-Label Study (MIROP Study).
    Kimura Y; Yamaguchi S; Suzuki T; Kato J; Chiba S; Hirakawa N; Yamaguchi K; Tanabe Y; Takatsuna H; Kenyoshi Y; Shiosakai K; Sakai M; Iseki M
    Pain Ther; 2021 Jun; 10(1):711-727. PubMed ID: 33856660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pharmacological, pharmacodynamics, and clinical profile of mirogabalin besylate (Tarlige
    Kitano Y; Kai K; Yamamura N; Yoshiba S; Kuroha M
    Nihon Yakurigaku Zasshi; 2019; 154(6):352-361. PubMed ID: 31787689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of mirogabalin for chemotherapy-induced peripheral neuropathy: a prospective single-arm trial (MiroCIP study).
    Misawa S; Denda T; Kodama S; Suzuki T; Naito Y; Kogawa T; Takada M; Suichi T; Shiosakai K; Kuwabara S;
    BMC Cancer; 2023 Nov; 23(1):1098. PubMed ID: 37951905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.